2006•Investigative Ophthalmology & Visual ScienceRequires access

Intravitreal Bevacizumab (Avastin) Therapy for Neovascular Age–Related Macular Degeneration: 6 Months Results of an Uncontrolled, Open Label Clinical Study

Gad Heilweil, Adiel Barak, Iris Moroz, Anat Loewenstein

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Macular degeneration, Medicine, Bevacizumab, Ophthalmology, Surgery, Chemotherapy

Back to paper search Browse research topics Original source

Intravitreal Bevacizumab (Avastin) Therapy for Neovascular Age–Related Macular Degeneration: 6 Months Results of an Uncontrolled, Open Label Clinical Study — Research Paper | ScholarLens